{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:47:36Z","timestamp":1782197256830,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Taihe Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bioenerg Biomembr"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10863-026-10116-y","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:07:07Z","timestamp":1782194827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting MEK1\/2 inhibits mitochondrial respiration and redox homeostasis in resistant rectal cancer"],"prefix":"10.1007","volume":"58","author":[{"given":"Hu","family":"Chenghao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chunli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Haixia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Guangyue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Xuefeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma","family":"JinLu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"10116_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"10116_CR2","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1200\/JCO.24.01160","volume":"42","author":"AJ Scott","year":"2024","unstructured":"Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, Cusnir M, Dorth J, George M, Kachnic LA, Kennecke HF, Loree JM, Morris VK, Perez RO, Smith JJ, Strickland MR, Gholami S (2024) Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol 42:3355\u20133375. https:\/\/doi.org\/10.1200\/JCO.24.01160","journal-title":"J Clin Oncol"},{"key":"10116_CR3","doi-asserted-by":"publisher","first-page":"151141","DOI":"10.1016\/j.bbrc.2024.151141","volume":"743","author":"H Chenghao","year":"2025","unstructured":"Chenghao H, Xuefeng L, Junli P, Ke W, Haixia L, Guangyue H, Qingqin L, Feng W (2025) Mitochondrial-targeting strategies with homoharringtonine: A novel approach for chemoresistant rectal cancer. Biochem Biophys Res Commun 743:151141. https:\/\/doi.org\/10.1016\/j.bbrc.2024.151141","journal-title":"Biochem Biophys Res Commun"},{"key":"10116_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.bbabio.2017.01.012","volume":"1858","author":"F Guerra","year":"2017","unstructured":"Guerra F, Arbini AA, Moro L (2017) Mitochondria and cancer chemoresistance. Biochim Biophys Acta Bioenerg 1858:686\u2013699. https:\/\/doi.org\/10.1016\/j.bbabio.2017.01.012","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"10116_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-022-01313-4","volume":"15","author":"P Jin","year":"2022","unstructured":"Jin P, Jiang J, Zhou L, Huang Z, Nice EC, Huang C, Fu L (2022) Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. J Hematol Oncol 15:97. https:\/\/doi.org\/10.1186\/s13045-022-01313-4","journal-title":"J Hematol Oncol"},{"key":"10116_CR6","doi-asserted-by":"publisher","unstructured":"Moindjie H, Rodrigues-Ferreira S, Nahmias C (2021) Mitochondrial Metabolism in Carcinogenesis and Cancer Therapy. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13133311","DOI":"10.3390\/cancers13133311"},{"key":"10116_CR7","doi-asserted-by":"publisher","unstructured":"Zhu Y, Xu J, Hu W, Wang F, Zhou Y, Xu W, Gong W, Shao L (2020) TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction. Gene 144807. https:\/\/doi.org\/10.1016\/j.gene.2020.144807","DOI":"10.1016\/j.gene.2020.144807"},{"key":"10116_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O\u2019Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT (2013) BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12:329\u2013341. https:\/\/doi.org\/10.1016\/j.stem.2012.12.013","journal-title":"Cell Stem Cell"},{"key":"10116_CR9","doi-asserted-by":"publisher","unstructured":"Adamopoulos C, Cave DD, Papavassiliou AG (2024) Inhibition of the RAF\/MEK\/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25031631","DOI":"10.3390\/ijms25031631"},{"key":"10116_CR10","doi-asserted-by":"publisher","first-page":"101065","DOI":"10.1016\/j.currproblcancer.2024.101065","volume":"49","author":"MS Lara","year":"2024","unstructured":"Lara MS, Blakely CM, Riess JW (2024) Targeting MEK in non-small cell lung cancer. Curr Probl Cancer 49:101065. https:\/\/doi.org\/10.1016\/j.currproblcancer.2024.101065","journal-title":"Curr Probl Cancer"},{"key":"10116_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2217\/fon-2018-0659","volume":"15","author":"A Indini","year":"2019","unstructured":"Indini A, Tondini CA, Mandala M (2019) Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival. Future Oncol 15:967\u2013977. https:\/\/doi.org\/10.2217\/fon-2018-0659","journal-title":"Future Oncol"},{"key":"10116_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.clml.2024.01.007","volume":"24","author":"MY Konopleva","year":"2024","unstructured":"Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee DR, Hamidi H, Ott MG, Hong WJ, Andreeff M (2024) Venetoclax and Cobimetinib in Relapsed\/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk 24:364\u2013374. https:\/\/doi.org\/10.1016\/j.clml.2024.01.007","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10116_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1200\/JCO.22.01000","volume":"41","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Geoerger B, Moertel C, Whitlock JA, Aerts I, Hargrave D, Osterloh L, Tan E, Choi J, Russo M, Fox E (2023) Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma. J Clin Oncol 41:664\u2013674. https:\/\/doi.org\/10.1200\/JCO.22.01000","journal-title":"J Clin Oncol"},{"key":"10116_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12943-017-0667-y","volume":"16","author":"G Cesi","year":"2017","unstructured":"Cesi G, Walbrecq G, Zimmer A, Kreis S, Haan C (2017) ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Mol Cancer 16:102. https:\/\/doi.org\/10.1186\/s12943-017-0667-y","journal-title":"Mol Cancer"},{"key":"10116_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1021\/cn500288n","volume":"6","author":"Q Ong","year":"2015","unstructured":"Ong Q, Guo S, Zhang K, Cui B (2015) U0126 protects cells against oxidative stress independent of its function as a MEK inhibitor. ACS Chem Neurosci 6:130\u2013137. https:\/\/doi.org\/10.1021\/cn500288n","journal-title":"ACS Chem Neurosci"},{"key":"10116_CR16","doi-asserted-by":"publisher","unstructured":"Farina F, Milani C, Botto L, Lonati E, Bulbarelli A, Palestini P (2016) Involvement of MEK-ERK1-2 pathway in the anti-oxidant response in C6 glioma cells after diesel exhaust particles exposure. Toxicol Lett 250\u2013251. https:\/\/doi.org\/10.1016\/j.toxlet.2016.04.008","DOI":"10.1016\/j.toxlet.2016.04.008"},{"key":"10116_CR17","doi-asserted-by":"publisher","unstructured":"Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1210093","DOI":"10.1056\/NEJMoa1210093"},{"key":"10116_CR18","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1158\/1535-7163.MCT-08-0972","volume":"8","author":"JJ Yeh","year":"2009","unstructured":"Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO, Der CJ (2009) KRAS\/BRAF mutation status and ERK1\/2 activation as biomarkers for MEK1\/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 8:834\u2013843. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0972","journal-title":"Mol Cancer Ther"},{"key":"10116_CR19","doi-asserted-by":"publisher","first-page":"26850","DOI":"10.1074\/jbc.M116.754762","volume":"291","author":"JB Collier","year":"2016","unstructured":"Collier JB, Whitaker RM, Eblen ST, Schnellmann RG (2016) Rapid Renal Regulation of Peroxisome Proliferator-activated Receptor gamma Coactivator-1alpha by Extracellular Signal-Regulated Kinase 1\/2 in Physiological and Pathological Conditions. J Biol Chem 291:26850\u201326859. https:\/\/doi.org\/10.1074\/jbc.M116.754762","journal-title":"J Biol Chem"},{"key":"10116_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","volume":"23","author":"R Haq","year":"2013","unstructured":"Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR (2013) Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 23:302\u2013315. https:\/\/doi.org\/10.1016\/j.ccr.2013.02.003","journal-title":"Cancer Cell"},{"key":"10116_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.freeradbiomed.2008.05.011","volume":"45","author":"SK Kim","year":"2008","unstructured":"Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, Lee KY, Jeong HG, Kang KW (2008) Increased expression of Nrf2\/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med 45:537\u2013546. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2008.05.011","journal-title":"Free Radic Biol Med"},{"key":"10116_CR22","doi-asserted-by":"publisher","first-page":"115036","DOI":"10.1016\/j.biopha.2023.115036","volume":"165","author":"X Zhou","year":"2023","unstructured":"Zhou X, An B, Lin Y, Ni Y, Zhao X, Liang X (2023) Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies. Biomed pharmacotherapy = Biomedecine pharmacotherapie 165:115036. https:\/\/doi.org\/10.1016\/j.biopha.2023.115036","journal-title":"Biomed pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"10116_CR23","doi-asserted-by":"publisher","unstructured":"Barrera G, Cucci MA, Grattarola M, Dianzani C, Muzio G, Pizzimenti S (2021) Control of Oxidative Stress in Cancer Chemoresistance: Spotlight on Nrf2 Role. Antioxid (Basel) 10. https:\/\/doi.org\/10.3390\/antiox10040510","DOI":"10.3390\/antiox10040510"},{"key":"10116_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","volume":"17","author":"AG Gilmartin","year":"2011","unstructured":"Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, Zappacosta F, Annan R, Sutton D, Laquerre SG (2011) GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17:989\u20131000. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2200","journal-title":"Clin Cancer Res"},{"key":"10116_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.18773\/austprescr.2016.095","volume":"40","author":"Cobimetinib for metastatic melanoma","year":"2017","unstructured":"Cobimetinib for metastatic melanoma (2017) Aust Prescr 40:30\u201331. https:\/\/doi.org\/10.18773\/austprescr.2016.095","journal-title":"Aust Prescr"},{"key":"10116_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1412690","journal-title":"N Engl J Med"},{"key":"10116_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11523-022-00888-9","volume":"17","author":"T Trippett","year":"2022","unstructured":"Trippett T, Toledano H, Campbell Hewson Q, Verschuur A, Langevin AM, Aerts I, Howell L, Gallego S, Rossig C, Smith A, Patel D, Pereira LR, Cheeti S, Musib L, Hutchinson KE, Devlin C, Bernardi R, Geoerger B (2022) Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I\/II Study. Target Oncol 17:283\u2013293. https:\/\/doi.org\/10.1007\/s11523-022-00888-9","journal-title":"Target Oncol"},{"key":"10116_CR28","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1080\/14796694.2024.2395235","volume":"20","author":"CD Lopez","year":"2024","unstructured":"Lopez CD, Kardosh A, Chen EY, Pegna G, Guimaraes A, Foster B, Brinkerhoff B, Goodyear SM, Lim JY, Taber E, Rajagopalan B, Edmerson E, Vo J, Nelson K, Jackson A, Gingerich T, Fahlman A, Lessenich C, Fennell F, Ventura D, Roy P, Keith D, Sheppard B, Brody JR, Mills GB, Ronai ZA (2024) Sears, CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Future Oncol 20:2915\u20132925. https:\/\/doi.org\/10.1080\/14796694.2024.2395235","journal-title":"Future Oncol"},{"key":"10116_CR29","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","volume":"29","author":"J Tian","year":"2023","unstructured":"Tian J, Chen JH, Chao SX, Pelka K, Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J, Mehta A, Oka T, Huang M, Lieb D, Spurrell M, Allen JN, Abrams TA, Clark JW, Enzinger AC, Enzinger PC, Klempner SJ, McCleary NJ, Meyerhardt JA, Ryan DP, Yurgelun MB, Kanter K, Van Seventer EE, Baiev I, Chi G, Jarnagin J, Bradford WB, Wong E, Michel AG, Fetter IJ, Siravegna G, Gemma AJ, Sharpe A, Demehri S, Leary R, Campbell CD, Yilmaz O, Getz GA, Parikh AR, Hacohen N, Corcoran RB (2023) Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial. Nat Med 29:458\u2013466. https:\/\/doi.org\/10.1038\/s41591-022-02181-8","journal-title":"Nat Med"},{"key":"10116_CR30","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","volume":"29","author":"S Leboulleux","year":"2023","unstructured":"Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, Benisvy D, Taieb D, Bardet S, Terroir-Cassou-Mounat M, Anizan N, Bouvier-Morel E, Lamartina L, Lion G, Betrian S, Sajous C, Schiazza A, Garcia ME, Ciappuccini R, Schlumberger M, Al Ghuzlan A, Godbert Y, Borget I (2023) A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer. Clin Cancer Res 29:2401\u20132409. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0046","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Bioenergetics and Biomembranes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10863-026-10116-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10863-026-10116-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10863-026-10116-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:07:07Z","timestamp":1782194827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10863-026-10116-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10116"],"URL":"https:\/\/doi.org\/10.1007\/s10863-026-10116-y","relation":{},"ISSN":["0145-479X","1573-6881"],"issn-type":[{"value":"0145-479X","type":"print"},{"value":"1573-6881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This procedure was approved by the Institutional Animal Care and Use Committee (IACUC No. 2021-16B).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}